Lantheus Holdings, Inc. (LNTH) Stock

Lantheus Holdings, Inc. (LNTH) is a Healthcare stock trading at $104.81 (as of 2026-07-24), with a market capitalization of $6.82B and a trailing P/E of 22.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Understand Lantheus Holdings, Inc.: how it makes money

Lantheus makes and sells medical imaging and precision diagnostic products, including Polarify and DFINITY (ultrasound-enhancing agent), NeuroSeq, and SPECT products like Technolite, and it also earns revenue from strategic partnerships and other precision diagnostics.

The profit engine is the Polarify installed base, where dependable execution (Polarify On-Time In-Fold Dose Delivery Rate) and ongoing demand (Polarify Repeat Customer Rate and active ordering customers) need to be supported by a scaled manufacturing and facility network (Active Polarify Manufacturing Facilities and other facility activations).

Business quality (Solid): The operating KPIs provided are specific to Polarify and DFINITY, but the input data does not clearly show mutually exclusive official reportable segments, so segment-based analysis is limited.

Valuation: At 25× earnings, LNTH trades 47% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

Polarify customer stickiness and recurring demand: Polarify has a high Polarify Repeat Customer Rate (97 percent). Polarify also shows Polarify Active Ordering Customers (900) and Polarify Customers Ordering Regularly (700), supporting ongoing utilization.
Operational execution appears strong: Polarify delivery performance is high, with a Polarify On-Time In-Fold Dose Delivery Rate of 98 percent.
Market position in DFINITY: DFINITY shows DFINITY Market Share (United States Ultrasound-Enhancing Agent Market) of 80.0 percent.
Commercial momentum and infrastructure build-out: Polarify scaling is reflected in Polarify Patient Scans Since Launch (250000) and Polarify Patient Diagnoses and Staging Since Launch (300000). Active Polarify Manufacturing Facilities are listed as 20.

Bear case

Revenue mix includes smaller and development-linked items: Strategic Partnerships and Other Revenue is listed at 0.02 USD_B, and Investigational Usage Revenue for NAV4694 is 0.0 USD_B in the provided set, which can make near-term results more sensitive to partner and development outcomes.
Execution risk can directly affect the customer base: Polarify’s repeat demand depends on reliable operations, and the model is exposed to changes in Polarify On-Time In-Fold Dose Delivery Rate (98 percent in the provided data) and the ability to maintain capacity via active facilities (Active Polarify Manufacturing Facilities is 20).
Facility and rollout constraints may limit growth: Facility network metrics such as PSMA PET Manufacturing Facilities Activated (37) and Prostate Cancer Micro-Format Facility Network Activated Sites (21) indicate growth may require continued activation and operational ramp, which can be a timing and execution risk.

Valuation — source: SEC EDGAR (first-party)
Price	$104.81
Market Cap	$6.82B
P/E Ratio	22.9
EV / EBITDA	20.1
Price / Book	5.63
Price / Sales	4.51
DCF Value (model)	$81.66
DCF Upside vs Price	-22.1%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$1.54B
Net Margin	15.2%
Revenue Growth (YoY)	0.5%
EPS Growth (YoY)	-23.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	5.46 (safe)
Piotroski F-Score	5/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	22.9
Sector P/E (Healthcare)	21.2
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	7.9%
vs Industry	35.1%

Company
Sector	Healthcare
Industry	Pharmaceutical Products

Related Companies (Business model: Closed-End Fund; 8 closest by market cap; US-domiciled)

Data as of 2026-07-24.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.